Digital Therapeutic for Schizophrenia
A new smartphone app, CT-155, has shown promise in reducing negative symptoms of schizophrenia.
Developed by Boehringer Ingelheim and Click Therapeutics, CT-155 integrates psychosocial interventions using an adaptive goal-setting technique.
A prescription digital therapy has demonstrated that it can reduce the negative symptoms of schizophrenia.
- Phase 3 trial demonstrated good tolerability and no significant adverse events when administered with an antipsychotic treatment.
- An estimated 24 million people worldwide have schizophrenia, according to the World Health Organization.
People with schizophrenia often experience persistent delusions and hallucinations.
CT-155 is the first experimental prescription digital therapy to exhibit such results.
Author's summary: Digital therapeutic CT-155 reduces schizophrenia symptoms.
More News
- Dan's Daily: Jagr Back; Team USA Makes Demands; Penguins Changes
- Lagos abattoirs: 8 major slaughterhouses powering N328 billion beef market
- EPL: Awoniyi Struggles In Nottingham Forest’s Home Defeat To Chelsea
- Texas faces heightened wildfire threat amid ongoing drought
- Coffee's delicious journey from tiny bean to tasty brew
- Adams, Ejuke Fail To Help Sevilla Close Gap On Madrid After Defeat To Mallorca
- Chelsea enjoy thumping win at Forest - West London Sport
- Trump commutes George Santos' prison sentence out of pity: "Horribly mistreated!"